YorLabs Receives FDA Clearance for Zero-CapEx Intracardiac Imaging System

Oct 27, 2025
YorLabs has received FDA 510(k) clearance for its Intracardiac Imaging System, a zero-capex ultrasound platform designed for electrophysiology and interventional cardiology procedures. The system enables single-operator control and offers high-resolution, real-time imaging for cardiac interventions.

YorLabs has received U.S. Food and Drug Administration 510(k) clearance for its Intracardiac Imaging System, announced in a press release. The zero-capex ultrasound platform is designed to simplify workflow and reduce costs in electrophysiology and interventional cardiology procedures.

The system provides high-resolution, real-time imaging and allows single-operator control for a variety of intracardiac procedures. It integrates wirelessly into existing catheterization labs, enabling flexible deployment without requiring major equipment investments.

YorLabs said it plans a limited U.S. market release in 2026, followed by broader commercial rollout and clinical collaborations with leading centers in electrophysiology and interventional cardiology.

We hope you enjoyed this article

Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Free newsletter

Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

Market report

2025 Generative AI in Professional Services Report

Thomson Reuters

This report by Thomson Reuters explores the integration and impact of generative AI technologies, such as ChatGPT and Microsoft Copilot, within the professional services sector. It highlights the growing adoption of GenAI tools across industries like legal, tax, accounting, and government, and discusses the challenges and opportunities these technologies present. The report also examines professionals' perceptions of GenAI and the need for strategic integration to maximize its value.

Read more
Free, six days a week

Daily AI Brief: the AI news that matters, in your inbox.